Pfizer (PFE) Gets a Hold Rating from Credit Suisse


Credit Suisse analyst Vamil Divan maintained a Hold rating on Pfizer (NYSE: PFE) on October 12 and set a price target of $40. The company’s shares closed on Friday at $43.78, close to its 52-week high of $45.81.

According to TipRanks.com, Divan is a 1-star analyst with an average return of -1.6% and a 45.6% success rate. Divan covers the Healthcare sector, focusing on stocks such as Aimmune Therapeutics, Johnson & Johnson, and Merck & Company.

Pfizer has an analyst consensus of Moderate Buy, with a price target consensus of $43.73, a -0.1% downside from current levels. In a report issued on October 4, Independent Research also maintained a Hold rating on the stock with a $48 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $45.81 and a one-year low of $33.20. Currently, Pfizer has an average volume of 20M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts